Pipeline
Newzen-138
NewzenPharma has developed compositions and methods for treating prostate cancer by targeting DNA repair within cancer/tumor cells. The technology inhibits BER capacity in cancer cells without compromising normal cell growth, slowing down tumor growth and metastasis. Compared to currently available chemotherapy treatment options for castrate-resistant prostate cancer, these methods provide effective treatment with fewer side effects but Newzen-138 has no side effects.
Newzen-150
Newzen-150 is NewzenPharma’s groundbreaking antibody-based therapy, specifically designed to target cancer cells with precision. This project leverages advanced antibody technology to identify and attack cancerous cells, aiming to enhance treatment effectiveness and minimize side effects. Through Newzen-150, NewzenPharma is committed to delivering targeted cancer therapies that bring new hope to patients facing cancer.
Newzen-170
Newzen-170 is NewzenPharma’s cutting-edge cell therapy program, focused on advanced cancer treatment through the latest innovations in cellular engineering and immune modulation. This next-generation therapy leverages genetically modified cells to target and destroy cancer cells selectively, while sparing healthy tissues. By combining proprietary cell engineering technologies with enhanced targeting mechanisms, Newzen-170 offers a highly personalized approach to cancer treatment, adapting to individual patient profiles for optimized outcomes. This program reflects NewzenPharma’s commitment to redefining cancer care with therapies that provide durable responses, reduced side effects, and potential for long-term remission across diverse cancer types.